Kornimate/medical-research-clean huggingface dataset:
endogenous glucoseproduction in patients with type 2 diabetes mellitus during oral glucose and iv. glucose infusion

Conditions: Type 2 Diabetes Mellitus

Summary: we want to investigate how lack of glucagon suppression during an oral glucose tolerance test in patients with type 2 diabetes contributes to patients postprandial hyperglycemia.

patients with type 2 diabetes mellitus (t2dm) are not able to suppress their glucagon secretion after a meal or after ingestion of glucose. previous studies have shown that gastrointestinal hormones might play a role in this phenomenon. however, it has not yet been possible to determine whether this lack of glucagon suppression postprandially results in an increased endogenous glucose secretion, and thus is a factor in the patients postprandial hyperglycemia. we aim to perform oral glucose tolerance tests and isoglycemic intravenous glucose infusions with and without a continuous glucagon infusion in patients with t2dm and healthy control subjects. the glucagon infusion is aiming at copying the inappropriate "physiological" glucagon response observed in patients with t2dm.

Eligibility criteria:
inclusion criteria: patients with t2dm * caucasions above 35 years of age with diet and/or tablettreated t2dm of at -least three months (diagnosis acording to who) * normal haemoglobin * informed consent healthy subjects * normal fasting plasma glucose (fpg) and normal hba1c (according to the -world health organization (who) criteria) * normal haemoglobin * age above 35 years * informed consent exclusion criteria: * inflammatory bowel disease * nephropathy (serum creatinine \>150 µm and/or albuminuria) * severe liver disease (serum alanine aminotransferase (alat) and/or serum aspartate aminotransferase (asat) \>3×normal values) * pregnancy and/or breastfeeding * age above 80 years * any condition that the investigator feels would interfere with trial participation patients with t2dm healthy subjects * diabetes mellitus (dm) * prediabetes (impaired glucose tolerance and/or impaired fpg) * first degree relatives with dm * inflammatory bowel disease * intestinal resection and/or ostomy * nephropathy (serum creatinine \>150 µm and/or albuminuria * liver disease (alat and/or serum asat \>2×normal values) * pregnancy and/or breastfeeding * age above 80 years * any condition that the investigator feels would interfere with trial participation

Keywords: diabetes mellitus glucagon endogenous glucose production incretin hormones
effects of the interventions using multiple sensory integrations on preterm infants' stress-related outcomes

Conditions: Preterm Infants; Pain

Summary: frequent pain and distress may affect infants' brain and neural development, and highlight the need for relieve pain interventions. peripheral venous puncture procedures are an important source of preterm infants' pain and distress. brain development is mainly created by infant sensory experience. it becomes important, therefore, to relieve preterm infants' pain and distress using multiple sensory integrations during peripheral venous puncture procedures.the proposed 2-year study has specific aim: to compare the effects of different combination of sensory integrations on preterm infants' pain and distress before, during, and after peripheral venous puncture procedures.


Eligibility criteria:
inclusion criteria: * gestational age (ga) 28-37 weeks * post-menstrual age (pma) 29-38 weeks * postnatal age 3-28 days * sable condition (ntissscore ≦ 22) * apgar scores≧7 at 5 minutes after birth exclusion criteria: * neurologic impairment * congenital anomalies * surgery * severe growth restriction at birth * severe medical conditions requiring treatments
prevention of contrast-induced nephropathy

Conditions: Contrast-induced Nephropathy; Acute Renal Failure; Chronic Renal Failure

Summary: patients with pre-existing kidney disease are at high risk of acute renal failure when exposed to radio-contrast dyes, for example during a cardiac angiogram. the investigators hypothesize that an infusion of saline + furosemide + mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls.

patients with pre-existing kidney disease are at high risk of acute renal failure when exposed to radio-contrast dyes, for example during a cardiac angiogram. we hypothesize that an infusion of saline + furosemide + mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls. we define an episode of contrast nephropathy using the conventional often published definition of a 25% relative increase in serum creatinine or a 44 umol absolute increase in serum creatinine within 48 hours of contrast exposure.

Eligibility criteria:
inclusion criteria: * age \> 21 years * serum creatinine \> 150 umol/l * able and willing to provide informed consent exclusion criteria: * known hypersensitivity to contrast, furosemide, or mannitol * unable to tolerate a fluid load (e.g., acute pulmonary edema) * esrd, on dialysis * previous enrollment in this study or previous contrast administration with the last 2 weeks * refusal by treating physician

Keywords: contrast-induced nephropathy prevention renal failure cardiac angiogram
analysis of clinical features of chronic liver disease complicated with hepatopulmonary syndrome

Conditions: Hepatopulmonary Syndrome (HPS)

Summary: hepatopulmonary syndrome (hps) has unknown pathogenesis, limited treatment and poor prognosis. the onset of hps is insidious and easy to be ignored. many liver diseases such as "cirrhosis and related complications" are the core characteristics of beijing you 'an hospital, but the clinical characteristics of hps patients in the center are still unclear. the investigators plan to make the diagnosis of hps among chronic liver disease patients in the hospital according to the diagnostic criteria of hps proposed in the practice guidelines of the international society of liver transplantation in 2016, collect clinical data of hps participants, evaluate the severity, analyze and summarize clinical characteristics, and conduct management and follow-up. at the same time, the investigators collect blood samples for proteomics tests. in order to improve the diagnosis and treatment level of hps.

at present, the mechanism of hepatopulmonary syndrome is not clear. the researchers plan to use the extracted plasma for detection, protein extraction and quality control, and then proteolytic hydrolysis, computer detection, and bioinformatics analysis.

Eligibility criteria:
inclusion criteria: * chronic hepatitis agreed to venous blood collection exclusion criteria: * pneumonia, pulmonary vascular disease, interstitial pulmonary disease, copd, bronchial asthma, lung cancer and other primary pulmonary diseases, acute upper gastrointestinal bleeding.
a study of the pulmonary safety and pharmacokinetics of zolmitriptan inhalation powder

Conditions: Migraine

Summary: this study is an open-label, parallel group study to evaluate acute pulmonary safety and pharmacokinetics (pk) of two doses, separated by 2 hours, of cvt-427 zolmitriptan inhalation powder in three groups of adults: those with asthma, those who smoke and healthy volunteers.

the purpose of this study is to evaluate acute pulmonary safety and pk of cvt-427 zolmitriptan inhalation powder in the study populations.

Eligibility criteria:
inclusion criteria: * eligible subjects will be men or women aged 18 to 65 years inclusive; * body mass index (bmi) 18 to 30 kg/m2; * healthy adults must be in general good health with no clinically significant abnormalities that would affect ability to complete study. * subjects with asthma must be non-smokers who have a forced expiratory volume in one second (fev1) ≥ 60% of predicted for race, age, sex, and height; * subjects who smoke must have at least a 12-month, 0.5 pack of cigarettes per day history or the equivalent consumption of cigars and a positive result for plasma cotinine. exclusion criteria: * subjects with asthma will be excluded for more than 2 hospitalizations or emergency room visits, or more than 3 courses of systemic steroids in the past 12 months or 1 course within the past 8 weeks for respiratory illness; * asthma exacerbation within 8 weeks of before screening; * unscheduled or urgent visit to any medical facility for asthma-related problems within 8 weeks before screening; * history of intubation or intensive care unit admission for asthma in the past 5 years. * subjects who smoke will be excluded if they have intrinsic lung disease including asthma or chronic obstructive pulmonary disease (copd) with an fev1 of \<60% of predicted and a score of ≥2 on the medical research council dsypnea scale (mrc); * any cardiovascular risk factor or contraindication for the use of triptans * use of nonselective monamine oxidase inhibitors (maoi), serotonin reuptake inhibitors (ssris), propranolol, or cimetidine within 4 weeks prior to the screening visit, or planned use during the study; * positive serology test (hepatitis b virus surface antigen \[hbsag\], hepatitis c virus \[hcv\] antibody, human immunodeficiency virus \[hiv\] 1 \& 2 antibodies).

Keywords: adult smokers asthma healthy volunteers
effect aerobic training on women with breast cancer after chemotherapy

Conditions: Cancer; Exercise; Hemoglobins

Summary: introduction: the purpose of this study was to determine the effect of twelve weeks of aerobic exercise program on erythrocyte levels in women with breast cancer after chemotherapy. methods: thirty women with breast cancer after chemotherapy of sydalshhda hospital (aged between 47-65 years) volunteered for this study, and then randomly selected an exercise (n = 15) and control (n = 15) groups. exercise group completed a twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve, while the control group were followed. blood samples including red blood cell counts (rbc), hematocrit (hct), hemoglobin (hb), peak oxygen consumption before and after 12 weeks of aerobic exercise were measured. for analysis of data, repeated-measures analysis of variance (anova) was used.


Eligibility criteria:
inclusion criteria: women with breast cancer , who can do a physical, physiological and psychological test; and did not have exercise limitations due to neuromuscular and/or musculoskeletal disease; did not have any health problems that prevented maximum effort on the treadmill test. exclusion criteria: women under erythropoietin treatments, uncontrolled cardiovascular or pulmonary diseases, uncontrolled arrhythmias, orthopedic conditions that would limit exercise participation, refusal for randomization, or participation in aerobic exercise training within 3 months before beginning the study.
hair regeneration in androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: this clinical trial study aims to compare the effectiveness and safety of secretome from adscs with minoxidil in aga cases, to provide future reference or standard in the application of cell-based therapy and its derivatives in aga cases. the subject of this study is androgenetic alopecia population. the main questions it aims to answer are: * is the secretome of adsc's effective compared to minoxidil? * is the secretome of adsc's safe compared to minoxidil? * is the combination of the secretome of adsc's and minoxidil better in safety and effectiveness compared to secretome or minoxidil alone?

this study was a single-blind clinical trial using an experimental research design on subjects with androgenetic alopecia. variables tested in this study were the method of "treatment of aga by administering secretome concentrate alone, compared to using minoxidil alone and with a combination of both." subjects were divided into 3 groups: * 20 subjects received secretome * 20 subjects received minoxidil * 20 subjects received both treatments participants will undergo history taking, and a physical examination (including vital signs, body weight, and hair pull test). pictures of patients' head were then taken and the hair loss degree was graded using hamilton-norwood. hair growth was evaluated every month starting from months 0, 1, 2, and 3. clinical assessment of hair growth was examined through physical and supporting examinations including photography, trichoscan, and trichoscopy. the sample size for this study was calculated with the help of g\*power version 3.1 software (heinrich-heine-universität düsseldorf, düsseldorf, germany). the inclusion and exclusion criteria are applied. statistical data were analyzed using spss® version 21 software. on numerical data, normality analysis was carried out using the kolmogorov-smirnov test.

Eligibility criteria:
inclusion criteria: * male patients aged 18-59 years * clinical presentation of aga with hamilton-norwood grade iii-vi * willing to be a research subject, sign a consent form, and commit to regular follow-up visits exclusion criteria: * hair loss other than aga, including telogen effluvium, alopecia areata, trichotillomania, secondary syphilis, systemic lupus erythematosus hair loss due to chemotherapy, autoimmune conditions, or malignancies. * patients taking oral medications or vitamins aimed at increasing hair growth in the last month * patients applying topical medications aimed at increasing hair growth in the last 2 weeks * patients with active bacterial, viral, or fungal infections on the scalp * patients undergoing aga therapy cosmetic procedures in the form of prp injections, laser procedures, or micro-needling in the last 3 months

Keywords: secretome minoxidil skin androgenetic alopecia
intelligent moxibustion robot in the treatment of low back pain

Conditions: Moxibustion; Low Back Pain

Summary: the intelligent moxibustion robot is applied to the clinical treatment of low back pain to verify its effectiveness and safety

shanxi acupuncture and moxibustion hospital and north university of china jointly developed an "intelligent thunder-fire moxibustion" robot with six degrees of freedom mechanical arm as the core and will be applied in clinical practice to verify its clinical efficacy. in clinical practice, patients with low back pain were recruited jointly by several hospitals and divided into two groups. intelligent thunder-fire moxibustion robot and artificial thunder-fire moxibustion were respectively used for treatment. the clinical efficacy and safety of intelligent thunder-fire moxibustion robot were evaluated through comparative analysis of outcome indexes such as vas pain scale and serum inflammatory factors.

Eligibility criteria:
inclusion criteria: * 1.it is consistent with the diagnostic criteria of low back pain and the syndrome differentiation criteria of cold and wet lumbar muscle strain. * 2.there is no gender limitation, and the age should be between 25 and 70 years old * 3.no treatment of traditional chinese and western medicine related to lumbago was received in the past 2 weeks * 4.the course of disease was controlled within 8 years * 5.informed consent, willing to cooperate with the whole treatment * 6.agree to record the scale score and volunteer to participate in this experiment * 7.at least one contact information should be reserved for patients to receive follow-up visits * 8.in order to reduce the rate of shedding, priority is included in hospitalized patients exclusion criteria: * 1.patients do not meet the inclusion criteria patients who do not meet the diagnostic inclusion criteria of this subject * 2.the patient is in the pregnancy or lactation period * 3.patients are allergic to moxibustion smoke, and it is difficult to accept moxibustion treatment * 4.the patient suffers from diseases of the blood and immune system * 5.patients with cardiac, liver and renal insufficiency * 6.the patient suffers from mental illness and cannot cooperate with moxibustion * 7.the patient suffered from lumbar spine tuberculosis, bone cancer and other diseases, which affected the experimental results

Keywords: moxibustion low back pain robot randomized controlled trial
plasma s-adenosylhomocysteine levels and endothelial dysfunction

Conditions: Cardiovascular Diseases

Summary: to investigate the relationship betweeen plasma s-adenosylhomocysteine (sah) levels and endothelial dysfunction, we plan to enroll approximately 150 patients with high risk of cardiovascualr disease,who will be measaured the flow-mediated dilation by b-ultrasound, and then measaured the plasma levels of methionine metabolites, such as sah, sam, and analyze the association.

to investigate the relationship betweeen plasma s-adenosylhomocysteine (sah) levels and endothelial dysfunction, we plan to enroll approximately 150 patients with high risk of cardiovascualr disease,who will be measaured the flow-mediated dilation by b-ultrasound, and then use hplc-ms/ms to measaure the plasma levels of methionine metabolites, such as sah, sam, and use methylated specifical pcr to detect the promoter dna methylation of p66shc, and use elisa kits to measure the plasma ros levels of cvd patients, such as mda, 8-iso-prostaglandin f2a, and finally analyze the association between sah, ros levels, promoter dna methylation of p66shc, and flow-mediated dilation.

Eligibility criteria:
inclusion criteria: * patients who have stable clinical conditions, except for acute coronary syndromes, and the availability of measurement of flow-mediated dilation, or have more than three cardiovascular traditional risk factors, such as smoking, alcohol use, obesity, hypertesion, diabetes, family history, and so on. exclusion criteria: * critical illness or hemodynamic instability other than acute coronary syndromes, surgery, or trauma within the previous month, known cancer, hepatic failure or hepatitis, or the use of drugs, such as anticancer agents, which would affect plasma thcy concen-trations.

Keywords: s-adenosylhomocysteine endothelial function
risk factors and multiomics study of chronic kidney disease caused by metabolic diseases

Conditions: Chronic Kidney Diseases; Hypertension; Diabetes Mellitus; Hyperuricemia; Obesity

Summary: with the development of china's economy, people's living standard have improved, and the dietary structure have changed. metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in china. the pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. currently, it is believed that various mechanisms including the activation of renin-angiotensin-aldosterone system, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. so there must be some common pathogenesis. this study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.


Eligibility criteria:
inclusion criteria: * the diagnosis of metabolic diseases were confirmed; * be able to understand the process of the research; * volunteer for participation and be able to sign the informed consent. exclusion criteria: * age \ 80yrs; * patients with primary and secondary glomerular diseases * patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors; * contraindications for mri examination; * pregnant or lactation patients; * patients with unstable vital signs, failure of other organs or dysphoria.

Keywords: chronic kidney disease metabolic diseases biomarker functional imaging techniques
pupillary dilation during post-auricular vagal nerve stimulation

Conditions: Hearing Loss

Summary: the research team will evaluate pupillary dilation from vagal nerve stimulation of arnold's nerve, a branch of the vagus nerve, during routine cochlear implantation surgery.

the objective of this study is to determine if electrical stimulation of arnold's nerve, a branch of the vagus nerve, can result in vagal nerve response through the measurement of pupillary dilation

Eligibility criteria:
inclusion criteria: patients undergoing cochlear implantation: * will be undergoing surgery for a cochlear implant * is over the age of 18 * is willing to participate in the study patients undergoing vagal nerve stimulator implantation: * will be undergoing implantable vagal nerve stimulation * is over the age of 18 * is willing to participate in the study exclusion criteria: patients undergoing cochlear implantation: * is under the age of 18 * has history of prior ear surgery, congenital ear malformation, or cochlear implantation * pregnant or breastfeeding patients cannot undergo the standard-of-care implantation procedures required for participation in the study. * medical comorbidities resulting in exclusion are guided by the aans exclusion criteria for vns and include the following: * one vagus nerve * receiving other concurrent forms of brain stimulation * heart arrhythmias or other heart abnormalities * dysautonomias (abnormal functioning of the autonomic nervous system) * lung diseases or disorders (shortness of breath, asthma, etc.) * ulcers (gastric, duodenal, etc.) * vasovagal syncope (fainting) * pre-existing hoarseness patients undergoing vagal nerve stimulator implantation: * is under the age of 18 * has history of prior ear surgery, congenital ear malformation, or cochlear implantation * pregnant or breastfeeding * medical comorbidities resulting in exclusion are guided by the aans exclusion criteria for vns and include the following: * one vagus nerve * receiving other concurrent forms of brain stimulation * heart arrhythmias or other heart abnormalities * dysautonomias (abnormal functioning of the autonomic nervous system) * lung diseases or disorders (shortness of breath, asthma, etc.) * ulcers (gastric, duodenal, etc.) * vasovagal syncope (fainting) * pre-existing hoarseness